BlackRock Inc. Raises Position in Bristol Myers Squibb Company $BMY

BlackRock Inc. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 180,384,994 shares of the biopharmaceutical company's stock after acquiring an additional 8,702,106 shares during the period. BlackRock Inc. owned about 8.83% of Bristol Myers Squibb worth $10,393,783,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Northwestern Mutual Investment Management Company LLC boosted its holdings in shares of Bristol Myers Squibb by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company's stock valued at $3,509,000 after buying an additional 172 shares in the last quarter. KCM Investment Advisors LLC increased its stake in shares of Bristol Myers Squibb by 0.8% in the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company's stock worth $1,126,000 after acquiring an additional 174 shares in the last quarter. Sandy Cove Advisors LLC increased its stake in shares of Bristol Myers Squibb by 4.7% in the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company's stock worth $227,000 after acquiring an additional 176 shares in the last quarter. Investment Research Partners LLC lifted its position in Bristol Myers Squibb by 1.4% during the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company's stock valued at $708,000 after acquiring an additional 179 shares during the period. Finally, ESG Planning DBA Harper Investing grew its holdings in Bristol Myers Squibb by 1.3% in the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company's stock worth $745,000 after purchasing an additional 180 shares during the period. Institutional investors own 76.41% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on BMY shares. BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Guggenheim restated a "buy" rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. TD Cowen assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating for the company. Truist Financial restated a "buy" rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Piper Sandler began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an "overweight" rating for the company. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Trading Up 2.2%

Shares of NYSE:BMY opened at $66.07 on Wednesday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.10. The company has a market cap of $134.97 billion, a P/E ratio of 14.55, a PEG ratio of 0.17 and a beta of 0.22. The stock's fifty day moving average price is $59.94 and its 200-day moving average price is $59.14.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb's revenue for the quarter was up 5.7% on a year-over-year basis. During the same period last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source